Delcath Systems (DCTH)
Drug: Percutaneous Hepatic Perfusion
Abstract No. LBA8512Indication: Liver metastases from melanoma Clinical Trial: A phase III random assignment trial comparing percutaneous hepatic perfusion with melphalan (PHP-mel) to standard of care for patients with hepatic metastases from metastatic ocular or cutaneous melanoma. Presentation Time: Saturday, June 5. Oral session. Notes: Investors will get the first detailed look at data from the positive phase III study announced in April. ASCO did not release the PHP abstract Thursday night.